SCHEMBL8211131

SCHEMBL8211131

Cc1cc(C)c(C=C2C(=O)Nc3cc(-c4ccccc4)ccc32)[nH]1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 9/20 0.73
KDR P35968 8/20 0.73
PDGFRB P09619 6/20 0.73
ALK Q9UM73 5/20 0.73
FLT3 P36888 4/20 0.73
FGFR1 P11362 4/20 0.73
SRC P12931 3/20 0.73
CSF1R P07333 2/20 0.73
FLT1 P17948 2/20 0.73
FGFR3 P22607 2/20 0.73
MAPK1 P28482 2/20 0.73
FLT4 P35916 2/20 0.73
ABL1 P00519 2/20 0.73
PDPK1 O15530 2/20 0.73
MEN1 O00255 1/20 0.73
NPC1 O15118 1/20 0.73
GMNN O75496 1/20 0.73
USP2 O75604 1/20 0.73
LMNA P02545 1/20 0.73
MAPT P10636 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8211128 1.00 RET (0.73) RETKDRPDGFRBALKFLT3
SCHEMBL17480317 0.88 RET (0.62) RETKDRPDGFRBALKFLT3
SCHEMBL17480322 0.88 CHEK1 (0.66) RETKDRPDGFRBALKFLT3
SCHEMBL8199248 0.87 CHEK1 (0.70) RETKDRPDGFRBALKFLT3
SCHEMBL8199244 0.87 CHEK1 (0.70) RETKDRPDGFRBALKFLT3
Semaxanib SCHEMBL29351025 0.84 RET (1.00) RETKDRPDGFRBALKFLT3
Semaxanib SCHEMBL29373311 0.84 RET (1.00) RETKDRPDGFRBALKFLT3
Semaxanib SCHEMBL19572 0.84 RET (1.00) RETKDRPDGFRBALKFLT3
Semaxanib SCHEMBL28266617 0.84 RET (1.00) RETKDRPDGFRBALKFLT3
Semaxanib SCHEMBL19571 0.84 RET (1.00) RETKDRPDGFRBALKFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1999048868-A9 HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE SUGEN INC (US) 2000-04-20 WO disclosed